Skip to main content

Health Canada approved the ASCENT ASD research study of reSept ASD Occluder in Canada. Canada is the third country to authorize the enrollment of patients with atrial septal defects (ASD) in the clinical trial ASCENT ASD, following the United States and France. To date, over 75 patients have been successfully implanted as part of this study in over 20 sites.

“We are very pleased with the positive response of the Canadian health authorities and are looking forward to supporting the new local participating sites,” said atHeart Medical CEO Laurent Grandidier. “Canadian clinicians have a successful track record in pioneering innovation in cardiovascular intervention and we are delighted that they will contribute to the scientific body of evidence of reSept’s performance in patients.”

ASCENT ASD is a prospective, single-arm study evaluating the safety and efficacy of reSept ASD Occluder, the first occluder with a metal-free, bioresorbable frame, to treat patients with clinically significant, isolated ASDs. Primary endpoints will be compared with established performance goals of transcatheter ASD occluders currently available.

Please find further information on the ASCENT ASD trial here.